Andrea Galbiati

Dr. Andrea Galbiati

Philochem (Switzerland), Otelfingen, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
MBMatilde Bocci
Matilde Bocci
AZAureliano Zana
Aureliano Zana
LPLucrezia Principi
Lucrezia Principi
LLLaura Lucaroni
Laura Lucaroni
LPLuca Prati
Luca Prati
AGAndrea Galbiati
Andrea Galbiati

10 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AZAureliano Zana
Aureliano Zana
AGAndrea Galbiati
Andrea Galbiati
EGEttore Gilardoni
Ettore Gilardoni
MBMatilde Bocci
Matilde Bocci
JMJacopo Millul
Jacopo Millul
SCSamuele Cazzamalli
Samuele Cazzamalli
Purpose: Small molecule drug conjugates (SMDC) are modular anticancer prodrugs that include a tumor-targeting small organic ligand, a cleavable linker, and a potent cytotoxic agent. Most of the SMDC products that have been developed for clinical applications target internalizing tumor-associated antigens on the surface of tumor cells. We have recently described a novel non-internalizing small organic ligand (named OncoFAP) of fibroblast activation protein (FAP), a tumor-associated antigen highly expressed in the stroma of most solid human malignancies. Experimental Design: In this article, we describe a new series of OncoFAP-Drug derivatives based on monomethyl auristatin E (MMAE; a potent cytotoxic tubulin poison) and dipeptide linkers that are selectively cleaved by FAP in the tumor microenvironment. Results: The tumor-targeting potential of OncoFAP was confirmed in patients with cancer using nuclear medicine procedures. We used mass spectrometry methodologies to quantify the amount of prodrug delivered to tumors and normal organs, as well as the efficiency of the drug release process. Linkers previously exploited for anticancer drug conjugates were used as benchmark. We identified OncoFAP-Gly-Pro-MMAE as the best performing SMDC, which has now been prioritized for further clinical development. OncoFAP-Gly-Pro-MMAE selectively delivered more than 10% injected dose per gram of MMAE to FAP-positive tumors, with a tumor-to-kidney ratio of 16:1 at 24 hours post-injection. Conclusions: The FAP-specific drug conjugates described in this article promise to be efficacious for the targeting of human malignancies. The extracellular release of potent anticancer payloads mediates durable complete remission in difficult-to-treat animal models of cancer.

30 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAndrea Galbiati
Andrea Galbiati
MBMatilde Bocci
Matilde Bocci
SGSilvia Gervasoni
Silvia Gervasoni
EPEleonora Prodi
Eleonora Prodi
GMGiuliano Malloci
Giuliano Malloci
SCSamuele Cazzamalli
Samuele Cazzamalli

1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAndrea Galbiati
Andrea Galbiati
AZAureliano Zana
Aureliano Zana
PCPaola Conti
Paola Conti

2 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FBFrancesco Bartoli
Francesco Bartoli
PEPhilip H. Elsinga
Philip H. Elsinga
LNLuiza Reali Nazario
Luiza Reali Nazario
AZAureliano Zana
Aureliano Zana
AGAndrea Galbiati
Andrea Galbiati
PEPaola Erba
Paola Erba
FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for therapeutic applications. OncoFAP is an ultra-high-affinity ligand of FAP with a dissociation constant of 680 pM. OncoFAP has been recently discovered and clinically validated for PET imaging procedures in patients with solid malignancies. While more and more clinical validation is becoming available, the need for scalable and robust procedures for the preparation of this new class of radiopharmaceuticals continues to increase. In this article, we present the development of automated radiolabeling procedures for the preparation of OncoFAP-based radiopharmaceuticals for cancer imaging and therapy. A new series of [68Ga]Ga-OncoFAP, [177Lu]Lu-OncoFAP and [18F]AlF-OncoFAP was produced with high radiochemical yields. Chemical and biochemical characterization after radiolabeling confirmed its excellent stability, retention of high affinity for FAP and absence of radiolysis by-products. The in vivo biodistribution of [18F]AlF-NOTA-OncoFAP, a candidate for PET imaging procedures in patients, was assessed in mice bearing FAP-positive solid tumors. The product showed rapid accumulation in solid tumors, with an average of 6.6% ID/g one hour after systemic administration and excellent tumor-to-healthy organs ratio. We have developed simple, quick, safe and robust synthetic procedures for the preparation of theranostic OncoFAP-compounds based on Gallium-68, Lutetium-177 and Fluorine-18 using the commercially available FASTlab synthesis module.

20 February 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
GCGregorio Cullia
Gregorio Cullia
SBStefano Bruno
Stefano Bruno
SPSilvia Parapini
Silvia Parapini
MMMarilena Margiotta
Marilena Margiotta
LTLucia Tamborini
Lucia Tamborini
PCPaola Conti
Paola Conti